Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc., highlighting the company's strong financial performance and growing market adoption of its ZUNVEYL treatment in the long-term care sector. The company reported fourth quarter 2025 net product revenue of $2.5 million, contributing to a full fiscal year 2025 total revenue of $10.2 million, which included $6.8 million in ZUNVEYL sales. This performance indicates that Alpha Cognition is successfully commercializing its treatment and establishing a meaningful presence in the healthcare market.
Beyond the revenue figures, demand indicators showed particularly strong momentum, with bottles dispensed increasing 62% quarter-over-quarter to 4,941 units. December 2025 alone saw a record 1,859 bottles dispensed, suggesting accelerating adoption as the year concluded. The company's management views these metrics as evidence that ZUNVEYL is moving beyond initial trial use and becoming more integrated into facility treatment protocols, which is crucial for long-term commercial success in the healthcare industry.
The report noted that 729 long-term care homes were ordering ZUNVEYL, with 82% of those placing repeat orders. Additionally, 865 prescribers were involved with the treatment, and 69% of those were repeat prescribers. These statistics support the thesis that ZUNVEYL is gaining traction not just as an experimental option but as a standard component of care protocols in these facilities. This level of repeat business is particularly significant in healthcare markets where treatment protocols tend to be stable once established.
Alpha Cognition ended fiscal year 2025 with $66.0 million in cash, providing what management describes as sufficient runway into 2027 to continue scaling commercialization efforts. The company expects continued sequential sales growth throughout 2026, suggesting confidence in maintaining the current momentum. For those interested in reviewing the complete financial analysis and market assessment, the full announcement including downloadable images and additional materials is available at https://www.stonegateinc.com. The company's financial position and growth trajectory position it to potentially expand its market share in the competitive long-term care pharmaceutical sector.
